Earnings Call Summary | IRIDEX(IRIX.US) Q4 2023 Earnings Conference
Earnings Call Summary | IRIDEX(IRIX.US) Q4 2023 Earnings Conference
The following is a summary of the IRIDEX Corporation (IRIX) Q4 2023 Earnings Call Transcript:
以下是IRIDEX公司(IRIX)2023年第四季度業績電話會議記錄的摘要:
Financial Performance:
財務業績:
IRIDEX reported full-year revenue of $51.9 million in 2023, with Q4 revenue reaching $12.5 million.
The company experienced a net loss of $3 million in Q4, a decrease from $1.1 million in the previous year due to factors including reimbursement restrictions in the US and supply chain limitations.
The Q4 gross profit was $4.9 million, compared to $6.7 million in the same period of the previous year.
The company managed to reduce its Q4 net cash to the lowest in 2023 through cost-cutting measures.
IRIDEX報告稱,2023年全年收入爲5190萬美元,第四季度收入達到1,250萬美元。
由於美國的報銷限制和供應鏈限制等因素,該公司在第四季度淨虧損300萬美元,低於去年的110萬美元。
第四季度的毛利爲490萬美元,而去年同期爲670萬美元。
通過削減成本的措施,該公司設法將其第四季度的淨現金減少到2023年的最低水平。
Business Progress:
業務進展:
Despite the challenges, IRIDEX made strong progress in the glaucoma segment with significant presence at the World Glaucoma Congress.
The company expanded its clinical evidence base and increased utilization by launching a registry program in the UK.
FDA clearance was received for their new single spot platform for the IRIDEX 532 and 577 systems, strengthening their position in retina treatment.
They are strategizing to drive utilization across their existing installed base and build adoption among moderate-stage glaucoma patients.
In 2024, with improved business flows and resolved supply chain issues, the company anticipates a return to more normalized levels.
The company positioned itself for recovery as two new platforms were developed in the retina segment, with notable interest in the new IRIDEX PASCAL platform.
儘管面臨挑戰,IRIDEX在青光眼領域取得了長足的進展,並在世界青光眼大會上大放異彩。
該公司通過在英國啓動註冊計劃,擴大了其臨床證據基礎並提高了利用率。
其新的IRIDEX 532和577系統單點平台獲得了美國食品藥品管理局的批准,鞏固了他們在視網膜治療中的地位。
他們正在制定戰略,以提高現有設備群的利用率,並提高中期青光眼患者的採用率。
2024年,隨着業務流的改善和供應鏈問題的解決,該公司預計將恢復到更正常的水平。
隨着視網膜領域的兩個新平台的開發,該公司將自己定位爲復甦,人們對新的IRIDEX PASCAL平台產生了濃厚的興趣。
More details: IRIDEX IR
更多詳情: IRIDEX IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。
譯文內容由第三人軟體翻譯。